JP2007204381A - β-glucan-containing liposome for cosmetics - Google Patents
β-glucan-containing liposome for cosmetics Download PDFInfo
- Publication number
- JP2007204381A JP2007204381A JP2006021906A JP2006021906A JP2007204381A JP 2007204381 A JP2007204381 A JP 2007204381A JP 2006021906 A JP2006021906 A JP 2006021906A JP 2006021906 A JP2006021906 A JP 2006021906A JP 2007204381 A JP2007204381 A JP 2007204381A
- Authority
- JP
- Japan
- Prior art keywords
- liposome
- weight
- liposome dispersion
- cosmetics
- glucan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002502 liposome Substances 0.000 title description 199
- 239000002537 cosmetic Substances 0.000 title description 55
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 title description 35
- 229920002498 Beta-glucan Polymers 0.000 title description 35
- 239000006185 dispersion Substances 0.000 description 88
- 239000000843 powder Substances 0.000 description 48
- 210000003491 skin Anatomy 0.000 description 48
- 239000002245 particle Substances 0.000 description 39
- 230000000052 comparative effect Effects 0.000 description 37
- 238000011156 evaluation Methods 0.000 description 29
- 239000007788 liquid Substances 0.000 description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 27
- 239000012528 membrane Substances 0.000 description 26
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 22
- 230000000694 effects Effects 0.000 description 21
- 150000003904 phospholipids Chemical class 0.000 description 20
- 235000019645 odor Nutrition 0.000 description 18
- 239000000470 constituent Substances 0.000 description 16
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 13
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 13
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 13
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 13
- 238000000034 method Methods 0.000 description 12
- 238000002156 mixing Methods 0.000 description 12
- 238000004220 aggregation Methods 0.000 description 11
- 230000002776 aggregation Effects 0.000 description 11
- 239000011148 porous material Substances 0.000 description 11
- 239000011780 sodium chloride Substances 0.000 description 11
- -1 acyl sarcosinate Chemical compound 0.000 description 10
- 238000001125 extrusion Methods 0.000 description 10
- 239000008213 purified water Substances 0.000 description 10
- 229920000515 polycarbonate Polymers 0.000 description 9
- 239000004417 polycarbonate Substances 0.000 description 9
- 238000003860 storage Methods 0.000 description 9
- 229930182558 Sterol Natural products 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- 238000000605 extraction Methods 0.000 description 8
- 230000006872 improvement Effects 0.000 description 8
- 150000003432 sterols Chemical class 0.000 description 8
- 235000003702 sterols Nutrition 0.000 description 8
- 239000004094 surface-active agent Substances 0.000 description 8
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 7
- 239000006071 cream Substances 0.000 description 7
- 239000000284 extract Substances 0.000 description 7
- 229910052740 iodine Inorganic materials 0.000 description 7
- 239000011630 iodine Substances 0.000 description 7
- 239000006210 lotion Substances 0.000 description 7
- 230000003020 moisturizing effect Effects 0.000 description 7
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 7
- 239000002994 raw material Substances 0.000 description 7
- 239000002253 acid Substances 0.000 description 6
- 125000004442 acylamino group Chemical group 0.000 description 6
- 229910052783 alkali metal Inorganic materials 0.000 description 6
- 238000009826 distribution Methods 0.000 description 6
- 238000004108 freeze drying Methods 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000008346 aqueous phase Substances 0.000 description 5
- 150000001720 carbohydrates Chemical class 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 238000001556 precipitation Methods 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 239000008347 soybean phospholipid Substances 0.000 description 5
- 206010013786 Dry skin Diseases 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000003012 bilayer membrane Substances 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 4
- 230000002123 temporal effect Effects 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 235000013339 cereals Nutrition 0.000 description 3
- 238000013329 compounding Methods 0.000 description 3
- 238000007865 diluting Methods 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 230000036571 hydration Effects 0.000 description 3
- 238000006703 hydration reaction Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 150000003839 salts Chemical group 0.000 description 3
- 238000004513 sizing Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 235000007319 Avena orientalis Nutrition 0.000 description 2
- 244000075850 Avena orientalis Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 229920001503 Glucan Polymers 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 108010077895 Sarcosine Proteins 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- XHRPOTDGOASDJS-UHFFFAOYSA-N cholesterol n-octadecanoate Natural products C12CCC3(C)C(C(C)CCCC(C)C)CCC3C2CC=C2C1(C)CCC(OC(=O)CCCCCCCCCCCCCCCCC)C2 XHRPOTDGOASDJS-UHFFFAOYSA-N 0.000 description 2
- XHRPOTDGOASDJS-XNTGVSEISA-N cholesteryl stearate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCCCCCCCCCCCC)C1 XHRPOTDGOASDJS-XNTGVSEISA-N 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000002296 dynamic light scattering Methods 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000000887 hydrating effect Effects 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229940042880 natural phospholipid Drugs 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 229960003975 potassium Drugs 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 229940043230 sarcosine Drugs 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000036558 skin tension Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 230000007306 turnover Effects 0.000 description 2
- QYIXCDOBOSTCEI-QCYZZNICSA-N (5alpha)-cholestan-3beta-ol Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 QYIXCDOBOSTCEI-QCYZZNICSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- GDFAOVXKHJXLEI-VKHMYHEASA-N N-methyl-L-alanine Chemical compound C[NH2+][C@@H](C)C([O-])=O GDFAOVXKHJXLEI-VKHMYHEASA-N 0.000 description 1
- 241000209504 Poaceae Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- PRLUQOOFPFWUKQ-KKTNLPSRSA-N [(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl] (z)-octadec-9-enoate Chemical compound C1C[C@@H]2[C@@]3(C)CC[C@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)C[C@@H]3CC[C@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@]21C PRLUQOOFPFWUKQ-KKTNLPSRSA-N 0.000 description 1
- XKMYWNHZAQUEPY-YZGJEOKZSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] 12-hydroxyoctadecanoate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCCCCCC(O)CCCCCC)C1 XKMYWNHZAQUEPY-YZGJEOKZSA-N 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229960003767 alanine Drugs 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- QYIXCDOBOSTCEI-UHFFFAOYSA-N alpha-cholestanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 QYIXCDOBOSTCEI-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000005388 borosilicate glass Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 229940072104 cholesteryl hydroxystearate Drugs 0.000 description 1
- WCLNGBQPTVENHV-MKQVXYPISA-N cholesteryl nonanoate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCCC)C1 WCLNGBQPTVENHV-MKQVXYPISA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 150000002339 glycosphingolipids Chemical class 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- 231100000245 skin permeability Toxicity 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Landscapes
- Cosmetics (AREA)
Abstract
【課題】 β−グルカンをリポソーム分散液へ含有させることで、経時安定性の良い（沈殿・凝集が生じないこと、においに変化のないこと）、べたつき感がなくさらさらとした感触で、肌あれを改善し、潤いのあるなめらかな肌へと導く、β−グルカン含有化粧料用リポソーム分散液、およびそのリポソーム分散液を用いた化粧料を提供すること。
【解決手段】 膜構成成分にホスファチジルコリン含量９０重量％以上、ヨウ素価０．１以下である水素添加大豆リン脂質を含み、β-グルカンを含有するリポソーム分散液で、リポソームの平均粒径が１００〜５００ｎｍであることを特徴とする化粧料用リポソーム分散液。
【選択図】 なし
PROBLEM TO BE SOLVED: To contain β-glucan in a liposome dispersion, which has good stability over time (no precipitation / aggregation occurs, no change in odor), no stickiness, and a smooth feel The present invention provides a β-glucan-containing cosmetic liposome dispersion for improving cosmetic properties and leading to moist and smooth skin, and a cosmetic using the liposome dispersion.
SOLUTION: A liposome dispersion liquid containing a hydrogenated soybean phospholipid having a phosphatidylcholine content of 90% by weight or more and an iodine value of 0.1 or less as a membrane component, and containing β-glucan. A liposome dispersion for cosmetics, which is 500 nm.
[Selection figure] None
Description
本発明は、においの変化がなく、経時的に安定で、べたつき感がなくさらさらとした感触で、肌あれを改善し、潤いのあるなめらかな肌へと導く、β-グルカン含有化粧料用リポソーム分散液、化粧料用粉末リポソーム、およびそのリポソーム分散液または粉末リポソームを用いた化粧料に関する。 The present invention provides β-glucan-containing cosmetic liposomes that have no change in odor, are stable over time, have a smooth feel without stickiness, improve skin roughness, and lead to moist and smooth skin. The present invention relates to a dispersion, a powder liposome for cosmetics, and a cosmetic using the liposome dispersion or powder liposome.
β−グルカンは、グルコースを構成単位とする多糖類である。１，３−、１，４−、１，３−と１，４−、１，３−と１，６−結合をしたものがあり、１，３−と１，４−結合型のβ−グルカンは穀物由来のものに多く含有され、１，３−と１，６−結合型のグルカンは酵母由来のものに多く含有される。
老化した皮膚は、乾燥してなめらかさのない肌となり、角質細胞剥離現象が認められ、さらに、ターンオーバー速度が遅く、肌がざらついてしまう。β−グルカンは、この老化した肌のターンオーバーを促進し、肌あれを改善する効果を持つことが知られており、皮膚化粧料として開発されている（特許文献１および２）。しかしながら、これらの化粧料は、多糖類であるため、特有のつっぱり感があり、使用時の肌への伸び、また使用後の肌触りに問題があった。
保湿効果を付与し、肌への浸透性を向上させて、肌あれ改善効果を高めるため、β−グルカンを含有したリポソーム化粧料が開発された（特許文献３および４）が、リポソームの構成成分であるリン脂質に天然リン脂質やスフィンゴ糖脂質を使用しているもので、リン脂質についての純度規定はなく、リポソームとしての安定性が十分ではなく、さらに使用時の感触においても満足できるものではなかった。
リポソームは、生体膜の主要構成成分であるリン脂質の二分子膜からなるナノサイズの閉鎖小胞体であり、古くからその皮膚浸透機能などが注目されており医薬品、化粧品などに使用されている。
しかしながら、天然リン脂質を原料とした従来のリポソームは、色や臭いが悪く、また経時安定性も悪かったため、クリームやジェル等のゲル状あるいは粘性の高い形態での使用しかできず、臭いを防ぐ為には香料の添加等が必要であった。そのため、無香料、微香性化粧料には適用が難しく、安定性にも問題があるため化粧水、乳液等の使用にも使用しづらいものであった。
そこで、本発明者らは、β−グルカンのつっぱり感と肌への伸び、また使用後の肌触りを改善すべく、鋭意研究を行った結果、ある特定のリン脂質を用いたリポソーム分散液へ含有させることで、経時安定性がよく、使用感のよい、またなめらかな肌へと改善効果のあるβ−グルカン含有リポソーム分散液を開発するに至った。
本発明は、安全性が高く、さらに使用感のよいβ−グルカン含有リポソーム分散液であり、荒れた肌を整え、つるつるとしたなめらかな肌へと改善する、β−グルカン含有リポソーム分散液である。
β-glucan is a polysaccharide having glucose as a structural unit. 1,3-, 1,4-, 1,3- and 1,4-, 1,3- and 1,6-bonded, and 1,3- and 1,4-linked β- Glucan is abundant in those derived from cereals, and 1,3- and 1,6-linked glucans are abundant in those derived from yeast.
Aged skin becomes dry and non-smooth skin, a keratinocyte peeling phenomenon is observed, the turnover speed is slow, and the skin becomes rough. β-glucan is known to have an effect of accelerating the turnover of aging skin and improving skin roughness, and has been developed as a skin cosmetic (Patent Documents 1 and 2). However, since these cosmetics are polysaccharides, they have a specific feeling of tension, and have problems with elongation to the skin during use and touch after use.
Liposome cosmetics containing β-glucan have been developed to impart a moisturizing effect, improve skin permeability, and improve skin roughness (Patent Documents 3 and 4). Natural phospholipids and glycosphingolipids are used for the phospholipids, and there is no purity regulation for phospholipids, the stability as liposomes is not sufficient, and the feel during use is not satisfactory. There wasn't.
Liposomes are nano-sized closed vesicles composed of bilayer membranes of phospholipids, which are the main constituents of biological membranes, and their skin permeation function has attracted attention for a long time, and is used in pharmaceuticals, cosmetics and the like.
However, conventional liposomes made from natural phospholipids have poor color and odor, and have poor stability over time, so they can only be used in gel or viscous forms such as creams and gels, preventing odors. For this purpose, addition of a fragrance or the like was necessary. Therefore, since it is difficult to apply to unscented and slightly fragrant cosmetics and there is a problem with stability, it has been difficult to use in the use of lotions, emulsions and the like.
Therefore, the present inventors have conducted intensive research to improve the feeling of tension of β-glucan and elongation to the skin, and the touch after use, and as a result, contained in a liposome dispersion using a specific phospholipid. As a result, a β-glucan-containing liposome dispersion having good stability over time, good usability, and an improvement effect on smooth skin has been developed.
The present invention is a β-glucan-containing liposome dispersion liquid that is highly safe and easy to use, and is a β-glucan-containing liposome dispersion liquid that improves rough skin and smooth skin that is smooth and smooth. .
本発明は、β−グルカンをリポソームへ含有させることで、経時安定性の良い（沈殿・凝集が生じないこと、においに変化のないこと）、べたつき感がなくさらさらとした感触で、肌あれを改善し、潤いのあるなめらかな肌へと導く、β−グルカン含有化粧料用リポソーム分散液、およびそのリポソーム分散液を用いた化粧料を提供するものである。 By incorporating β-glucan into liposomes, the present invention has good temporal stability (no precipitation / aggregation occurs, no change in odor), no sticky feeling, and a smooth feel, It is intended to provide a β-glucan-containing cosmetic liposome dispersion that leads to smooth and moisturized skin, and a cosmetic using the liposome dispersion.
本発明者らは、使用感の優れた安定なβ−グルカン含有化粧料用リポソームを得るべく鋭意研究した結果、リポソームの安定性において、リポソームを構成するリン脂質が大きく関与していることがわかった。
本発明のβ−グルカン含有化粧料用リポソーム分散液は、高純度水素添加大豆リン脂質を使用して、リポソームの粒径を整えることで、保存安定性がよく、さらに、べたつき感がなく、さらさらとした感触で、肌あれを改善し、潤いのあるなめらかな肌へと導くβ−グルカン含有化粧料用リポソーム分散液となることを見出した。
すなわち、本発明は以下に示されるものである。
（１） 膜構成成分にホスファチジルコリン含量９０重量％以上、ヨウ素価０．１以下である水素添加大豆リン脂質を含み、β-グルカンを含有するリポソーム分散液で、リポソームの平均粒径が１００〜５００ｎｍであることを特徴とする化粧料用リポソーム分散液。
（２） さらに膜構成成分にステロール類を含有することを特徴とする前記の化粧料用リポソーム分散液。
（３） アシルアミノ酸系界面活性剤を含有することを特徴とする前記の化粧料用リポソーム分散液。
（４） アシルアミノ酸系界面活性剤がアシルサルコシネートである前記の化粧料用リポソーム分散液。
（５） 前記の化粧料用リポソーム分散液を乾燥して得られる、水分が３重量％以下であることを特徴とする化粧料用粉末リポソーム。
（６） １価のアルカリ金属塩を膜構成成分１００重量％に対して２０重量％以下含有することを特徴とする前記の化粧料用粉末リポソーム。
（７） 前記の化粧料用リポソーム分散液または化粧料用粉末リポソームを０．１〜２０重量％含有することを特徴とする化粧料。
As a result of intensive studies to obtain stable β-glucan-containing cosmetic liposomes with excellent usability, the present inventors have found that the phospholipids constituting the liposomes are largely involved in the stability of the liposomes. It was.
The β-glucan-containing cosmetic liposome dispersion of the present invention uses high-purity hydrogenated soybean phospholipids to adjust the particle size of the liposomes, so that it has good storage stability and is not sticky. It was found that the liposome dispersion for cosmetics containing β-glucan improves the roughness of the skin and leads to smooth and moist skin.
That is, the present invention is as follows.
(1) Liposome dispersion containing a hydrogenated soybean phospholipid having a phosphatidylcholine content of 90% by weight or more and an iodine value of 0.1 or less as a membrane component and containing β-glucan, and having an average liposome particle size of 100 to 500 nm A liposome dispersion for cosmetics, wherein
(2) The cosmetic liposome dispersion described above, further comprising a sterol as a membrane component.
(3) The said liposome dispersion liquid for cosmetics characterized by containing an acylamino acid type surfactant.
(4) The said liposome dispersion liquid for cosmetics whose acylamino acid type surfactant is acyl sarcosinate.
(5) A powder liposome for cosmetics, which is obtained by drying the liposome dispersion liquid for cosmetics and has a water content of 3% by weight or less.
(6) The cosmetic powder liposome described above, which contains a monovalent alkali metal salt in an amount of 20% by weight or less based on 100% by weight of the membrane constituent.
(7) A cosmetic comprising 0.1 to 20% by weight of the cosmetic liposome dispersion or cosmetic powder liposome.
本発明は、β−グルカンをリポソーム分散液へ含有させることにより、経時安定性の良い（沈殿・凝集が生じないこと、においの変化がないこと）、べたつき感がなく、さらさらとした感触で、肌あれを改善し、潤いのあるなめらかな肌へと導くβ−グルカン含有化粧料用リポソーム分散液で、化粧料に配合することにより、肌荒れ改善効果のある保湿性の高い、使用感のよい化粧料を得ることができる。 By incorporating β-glucan into the liposome dispersion, the present invention has good temporal stability (no precipitation / aggregation occurs, no change in odor), no stickiness, and a smooth feel. A beta-glucan-containing cosmetic liposome dispersion that improves skin roughness and leads to smooth and moisturized skin. By blending it into cosmetics, it is highly moisturizing and has a good feeling of use. You can get a fee.
本発明の化粧料用リポソーム分散液は、ホスファチジルコリン含量９０重量％以上、ヨウ素価０．１以下である水素添加大豆リン脂質とβ-グルカンを含有し、リポソームの平均粒径が１００〜５００ｎｍであることを特徴とする化粧料用リポソームである。 The liposome dispersion for cosmetics of the present invention contains hydrogenated soybean phospholipid having a phosphatidylcholine content of 90% by weight or more and an iodine value of 0.1 or less and β-glucan, and the liposome has an average particle size of 100 to 500 nm. It is the liposome for cosmetics characterized by this.
本発明においてリポソーム分散液の膜構成成分として用いられる水素添加大豆リン脂質のホスファチジルコリン含量は９０重量％以上であり、好ましくは９５重量％以上である。ホスファチジルコリン含量が９０重量％以上であると、酸性リン脂質や脂肪酸などの不純物が存在しないため、二分子膜の相分離が生じにくくなるため、膜強度が強くなり、水の浸入を抑制し、アシル基の加水分解、また色やにおいなどの劣化が抑制される。さらには、ホスファチジルコリン含量が９０重量％以上のリン脂質を使用したリポソーム分散液は、べたつき感がなく、さらさらとしたなめらかな感触を強く感じる。
水素添加大豆リン脂質のヨウ素価は０．１以下、好ましくは０．０５以下である。ヨウ素価が０．１以下であると、色やにおいなどのリポソームの劣化が抑制される。
In the present invention, the phosphatidylcholine content of the hydrogenated soybean phospholipid used as a membrane constituent of the liposome dispersion is 90% by weight or more, preferably 95% by weight or more. If the phosphatidylcholine content is 90% by weight or more, impurities such as acidic phospholipids and fatty acids do not exist, and phase separation of the bilayer membrane is difficult to occur. Hydrolysis of the group and deterioration such as color and odor are suppressed. Furthermore, a liposome dispersion using a phospholipid having a phosphatidylcholine content of 90% by weight or more does not feel sticky and feels a smooth and smooth feel.
The iodine value of hydrogenated soybean phospholipid is 0.1 or less, preferably 0.05 or less. When the iodine value is 0.1 or less, deterioration of the liposome such as color and smell is suppressed.
本発明に用いられるβ−グルカンは、１，３−、１，４−、１，３−と１，４−、１，３−と１，６−結合のどの結合をしたβ−グルカンでもよく、穀物由来でも酵母由来または微生物由来であってもよい。
例えば、穀物由来であるβ−グルカンとしては、イネ科植物、大麦またはオーツ麦から抽出されるものが挙げられる。その抽出方法に特に制限はなく、抽出原料となるイネ科植物に、抽出溶媒を添加し抽出すればよい。また、固液分離された場合の抽出液そのもの、あるいは、抽出液より公知の方法で抽出されたβ−グルカンを濃縮した液体や固体状のもの、あるいは、抽出液より公知の方法で精製し純度を上げた液体や固体状のもの等、いずれの製造方法で得たものでも、いずれの形態のものでも、いずれの純度のものでも使用可能である。
本発明において抽出物とは、水（または熱水等）による抽出工程で水に含有されている成分（必ずしも完全に溶解している必要はない）であればよく、従って、例えば、抽出工程後にろ紙等でろ過したろ液や抽出液から濃縮、冷却等で析出した微粒子成分（凝集物等）もこの抽出物に含まれる。
また、抽出溶剤としては上記の水単独以外に、他の有機溶剤を使用することもできるが、水単独もしくは水以外に少量の有機溶剤を含む混合液が好ましく、このような水を含む溶液による抽出も当然本発明における水抽出に含まれる。
また、市販のβ−グルカン分散液など抽出された以外の成分が混合していても何ら問題はない。本発明では、これらをすべてβ−グルカンという。
The β-glucan used in the present invention may be any β-glucan having 1,3-, 1,4-, 1,3- and 1,4-, 1,3- and 1,6-linkages. It may be derived from cereals, yeasts or microorganisms.
For example, the β-glucan derived from cereals includes those extracted from gramineous plants, barley or oats. There is no particular limitation on the extraction method, and an extraction solvent may be added to the grass family as an extraction raw material for extraction. The purity of the extract itself after solid-liquid separation, or a liquid or solid obtained by concentrating β-glucan extracted from the extract by a known method, or purified from the extract by a known method It can be used in any form, in any form, or in any form, such as liquids or solids with a raised pH.
In the present invention, the extract may be any component (not necessarily completely dissolved) contained in water in the extraction step with water (or hot water or the like), and thus, for example, after the extraction step Particulate components (aggregates, etc.) precipitated from a filtrate or extract filtered through filter paper or the like by concentration, cooling, etc. are also included in this extract.
In addition to the above water alone, other organic solvents can also be used as the extraction solvent, but water alone or a mixed solution containing a small amount of an organic solvent other than water is preferred, and depending on such a solution containing water. Naturally, extraction is also included in the water extraction in the present invention.
Moreover, there is no problem even if components other than those extracted such as commercially available β-glucan dispersion are mixed. In the present invention, these are all referred to as β-glucan.
本発明におけるリポソーム分散液は、平均粒径１００〜５００ｎｍであることが好ましく、１５０〜３００ｎｍであることがさらに好ましい。本発明に用いる水素添加大豆リン脂質からなるリポソームは、リン脂質の分散力が弱いため、リポソーム調製時に十分に水和され、安定なリポソームを形成することが必要であるが、平均粒径５００ｎｍを超えるリポソームでは分散安定性が十分でなく、沈殿、凝集を生じやすい。また、平均粒径１００ｎｍ未満のリポソームでは、リポソームの曲率が高くなり、二分子膜構造にゆがみが生じやすいため、沈殿、凝集を生じやすくなる。
本発明の化粧料用リポソーム分散液を用いた化粧料の使用感は、リポソームの粒径と関係しており、平均粒径１００〜５００ｎｍであるものは、塗布時にべたつき感がなく、さらさらとした感触と肌のなめらかさを感じ、洗浄後もしっとり感を残して肌のなめらかさを持続するものである。平均粒径が５００ｎｍを超える場合には、塗布後、肌にざらつきを生じて、べたつき感を感じ、平均粒径１００ｎｍ未満の場合、リポソームの粒子感がなくなり、さらさらとした肌のなめらかさを感じることができない。
The liposome dispersion in the present invention preferably has an average particle size of 100 to 500 nm, and more preferably 150 to 300 nm. Liposomes composed of hydrogenated soybean phospholipids used in the present invention have a low phospholipid dispersibility, so that they need to be sufficiently hydrated during liposome preparation to form stable liposomes. In the case of the exceeding liposome, the dispersion stability is not sufficient, and precipitation and aggregation are likely to occur. In addition, liposomes with an average particle size of less than 100 nm have a high curvature and are likely to be distorted in the bilayer structure, so that precipitation and aggregation are likely to occur.
The feeling of use of the cosmetics using the liposome dispersion liquid for cosmetics of the present invention is related to the particle size of the liposomes, and those having an average particle size of 100 to 500 nm have no stickiness at the time of application and are smooth. It feels the touch and smoothness of the skin, and keeps the smoothness of the skin with a moist feeling after washing. When the average particle size exceeds 500 nm, the skin becomes rough after application and feels sticky. When the average particle size is less than 100 nm, the particle feeling of liposome disappears and the skin feels smooth and smooth. I can't.
本発明の化粧料用リポソームは、特定の配合の膜構成成分であることにより、特定の粒径を持つことができる。本発明における膜構成成分とは、水素添加大豆リン脂質、ステロール類である。
水素添加大豆リン脂質のホスファチジルコリン含量が９０重量％未満であると、粒径が大きくなる傾向があり、また、ヨウ素価が０．１を超えると粒径が大きくなる傾向がある。ホスファチジルコリン含量が高いほど、またヨウ素価が低いほど、リン脂質の疎水性が増加し、作製したリポソームの膜強度が高くなる。例えば、エクストルージョンを行った場合、膜強度の弱いリポソームはフィルター通過時にリポソームが変形しながら通過し、通過後にもとの球形に戻るため粒径が変化しにくいが、膜強度の高いリポソームは、フィルター通過時に変形しにくいため、リポソームがフィルターの孔径に合わせて再構成され、より小さな粒径で粒度分布のそろったリポソームが得られる傾向にある。
The liposome for cosmetics of the present invention can have a specific particle size by being a film component of a specific formulation. The membrane constituents in the present invention are hydrogenated soybean phospholipids and sterols.
When the phosphatidylcholine content of the hydrogenated soybean phospholipid is less than 90% by weight, the particle size tends to increase, and when the iodine value exceeds 0.1, the particle size tends to increase. The higher the phosphatidylcholine content and the lower the iodine value, the more hydrophobic the phospholipid and the higher the membrane strength of the liposomes produced. For example, when extrusion is performed, liposomes with weak membrane strength pass through the filter while deforming and return to the original spherical shape after passing, but the particle size is difficult to change, but liposomes with high membrane strength are Since it is difficult to be deformed when passing through the filter, the liposome is reconstituted according to the pore size of the filter, and there is a tendency to obtain a liposome having a smaller particle size and a uniform particle size distribution.
平均粒径は、ＮＩＣＯＭＰ粒度分布計（ＭＯＤＥＬ３７０）を用いて動的光散乱を測定することによって求められる。
本発明のリポソーム分散液は、ＮＩＣＯＭＰ粒度分布計において、希釈溶剤を水とし、リポソーム分散液を十分に希釈して、Ｖｅｓｉｃｌｅモードで測定を行い得られるＧａｕｓｓｉａｎ分布の平均粒径（体積換算）が１００〜５００ｎｍである。また、測定の際は、リポソームの変形や歪みを生じさせないように、調製したリポソームの浸透圧と希釈溶剤の浸透圧をそろえた方がよい。
The average particle size is determined by measuring dynamic light scattering using a NICOMP particle size distribution meter (MODEL 370).
The liposome dispersion liquid of the present invention has a Gaussian distribution average particle size (volume conversion) of 100 obtained by performing measurement in the vesicle mode by sufficiently diluting the liposome dispersion liquid with water as the diluent solvent in the NICOMP particle size distribution analyzer. ~ 500 nm. In the measurement, it is preferable that the osmotic pressure of the prepared liposome and the osmotic pressure of the diluting solvent are aligned so as not to cause deformation and distortion of the liposome.
本発明のリポソーム分散液は、水素添加大豆リン脂質を０．１〜２０重量％含有するのが好ましい。また、より好ましくは、０．５〜１０重量％、さらに好ましくは１〜５重量％である。本発明のリポソームは、水素添加大豆リン脂質を０．１重量％以上配合することで特有の感触と保湿効果を感じることができ、また、２０重量％含有することで十分な保湿効果を保有することができる。
本発明のリポソーム分散液は、β-グルカンを０．００１〜２重量％含有することが好ましく、さらに好ましくは０．０５〜１重量％である。本発明のリポソーム分散液はβ-グルカンを２重量％を超えて配合すると、リポソーム特有のさらさら感を消失してしまう傾向にある。また、０．００１重量％未満であるとき、β-グルカンの十分な効果が得られにくい。
β-グルカンは、リポソームの内水相でも外水相でも、またその両側にあってもさしつかえない。
The liposome dispersion of the present invention preferably contains 0.1 to 20% by weight of hydrogenated soybean phospholipid. Moreover, More preferably, it is 0.5 to 10 weight%, More preferably, it is 1 to 5 weight%. The liposome of the present invention can feel a unique feel and moisturizing effect by adding 0.1% by weight or more of hydrogenated soybean phospholipid, and possesses a sufficient moisturizing effect by containing 20% by weight. be able to.
The liposome dispersion of the present invention preferably contains 0.001 to 2% by weight of β-glucan, more preferably 0.05 to 1% by weight. When the liposome dispersion liquid of the present invention is blended with more than 2% by weight of β-glucan, there is a tendency for the smooth feeling peculiar to liposomes to disappear. Moreover, when it is less than 0.001% by weight, it is difficult to obtain a sufficient effect of β-glucan.
β-glucan can be present in the inner or outer aqueous phase of the liposome, or on both sides thereof.
本発明の化粧料用リポソーム分散液は、膜構成成分にさらにステロール類を配合することにより、膜の流動性を抑制し、経時安定性を高めることができる。ステロール類としては、例えば、コレステロール、フィトステロール、ジヒドロコレステロール、ステアリン酸コレステリル、ノナン酸コレステリル、ヒドロキシステアリン酸コレステリル、オレイン酸ジヒドロコレステリル等が挙げられる。好ましくは、コレステロール、フィトステロール、ステアリン酸コレステリルである。
本発明のリポソーム分散液は、水素添加大豆リン脂質、β-グルカンからなるリポソーム分散液であり、さらに好ましくはステロール類を含有するものである。
本発明のリポソーム分散液は、β-グルカン、膜構成成分である水素添加大豆リン脂質、ステロール類から構成されるとき、水素添加大豆リン脂質とステロール類の比率は、重量比で５／５〜９．９／０．１であるのが好ましく、６／４〜９／１であるのがより好ましく、７／３〜８／２であるのがさらに好ましい。
本発明のリポソーム分散液は、水素添加大豆リン脂質とステロール類を膜構成成分として、０．１〜２０重量％含有するのが好ましい。より好ましくは０．５〜１０重量％、さらに好ましくは１〜５重量％である。
The liposome dispersion for cosmetics of the present invention can suppress the fluidity of the membrane and enhance the stability over time by further blending sterols with the membrane constituents. Examples of sterols include cholesterol, phytosterol, dihydrocholesterol, cholesteryl stearate, cholesteryl nonanoate, cholesteryl hydroxystearate, dihydrocholesteryl oleate, and the like. Cholesterol, phytosterol, and cholesteryl stearate are preferable.
The liposome dispersion of the present invention is a liposome dispersion composed of hydrogenated soybean phospholipid and β-glucan, and more preferably contains sterols.
When the liposome dispersion liquid of the present invention is composed of β-glucan, hydrogenated soybean phospholipid that is a membrane component, and sterols, the ratio of hydrogenated soybean phospholipid to sterols is 5/5 to 5/5 by weight. It is preferably 9.9 / 0.1, more preferably 6/4 to 9/1, and even more preferably 7/3 to 8/2.
The liposome dispersion of the present invention preferably contains 0.1 to 20% by weight of hydrogenated soybean phospholipid and sterols as membrane components. More preferably, it is 0.5-10 weight%, More preferably, it is 1-5 weight%.
本発明において、さらに、アシルアミノ酸系界面活性剤を含有することにより、リポソームの分散安定性を改良し、経時安定性の優れたリポソーム分散液を得ることができる。
これらのアシルアミノ酸系界面活性剤は、通常化粧料に用いられるものであれば、特には限定されず、具体的には、グルタミン酸、タウリン、グリシン、サルコシン、アラニン、メチルアラニンなどのアミノ酸の炭素数１０〜２２の脂肪酸アミドのナトリウム、カリウム、トリエタノールアミンより選ばれる塩であることが好ましく、サルコシンのアシル基の炭素数１２〜１８の脂肪酸アミドがリポソームの分散安定性により好ましく、炭素数１２の脂肪酸アミドがさらに好ましい。また、塩としてナトリウム、カリウムが好ましく、特にナトリウム塩が好ましい。
本発明のリポソーム分散液は、アシルアミノ酸系界面活性剤をリポソームの膜構成成分に対して０．２〜４重量％配合するのが好ましい。より好ましくは０．３〜３重量％、さらに好ましくは０．５〜２重量％である。
アシルアミノ酸系界面活性剤は、リポソームの膜構成物質に対して０．２重量％未満であった場合、リポソームの分散安定性への効果が十分でない可能性がある。また、４重量％を超える場合には、リポソームの二分子膜が弱くなり、二分子膜中のリン脂質のアシル基が加水分解されやすいため、経時安定性が低下する。
In the present invention, by further containing an acylamino acid surfactant, it is possible to improve the dispersion stability of the liposome and obtain a liposome dispersion having excellent temporal stability.
These acylamino acid surfactants are not particularly limited as long as they are usually used in cosmetics. Specifically, the number of carbon atoms of amino acids such as glutamic acid, taurine, glycine, sarcosine, alanine, and methylalanine. It is preferably a salt selected from sodium, potassium and triethanolamine of a fatty acid amide having 10 to 22, a fatty acid amide having 12 to 18 carbon atoms of the acyl group of sarcosine is preferable due to the dispersion stability of the liposome, and having 12 carbon atoms. More preferred are fatty acid amides. Moreover, sodium and potassium are preferable as a salt, and a sodium salt is particularly preferable.
In the liposome dispersion liquid of the present invention, the acylamino acid surfactant is preferably blended in an amount of 0.2 to 4% by weight based on the membrane constituents of the liposome. More preferably, it is 0.3 to 3 weight%, More preferably, it is 0.5 to 2 weight%.
If the acylamino acid surfactant is less than 0.2% by weight based on the membrane constituent material of the liposome, the effect on the dispersion stability of the liposome may not be sufficient. On the other hand, when it exceeds 4% by weight, the bilayer membrane of the liposome becomes weak and the acyl group of the phospholipid in the bilayer membrane is easily hydrolyzed, so that the stability over time is lowered.
本発明における水素添加大豆リン脂質は、天然大豆由来のリン脂質を精製して得られるものである。水素添加大豆リン脂質は、大豆リン脂質を水とヘキサンやアルコールなどと２相分配により抽出精製してから水素添加をすることにより得ることができる。また、水素添加された大豆リン脂質をアセトンやアルコールなどの溶媒を用いて晶析精製してもよいし、液相クロマトグラフィーなどにより分離精製しても得ることができる。 The hydrogenated soybean phospholipid in the present invention is obtained by purifying phospholipid derived from natural soybean. Hydrogenated soybean phospholipids can be obtained by extracting and purifying soybean phospholipids with water, hexane, alcohol, or the like by two-phase partitioning, followed by hydrogenation. The hydrogenated soybean phospholipid may be purified by crystallization using a solvent such as acetone or alcohol, or may be obtained by separation and purification by liquid phase chromatography or the like.
本発明の化粧料用リポソーム分散液には、上記成分の他に、通常化粧料として配合される成分として、水性成分、アルコール、油剤、界面活性剤、粉体、水溶性高分子、動植物由来の天然エキス、各種の栄養成分、保湿剤、細胞賦活剤、紫外線吸収剤、酸化防止剤、防腐剤、香料、無機塩、各種薬剤等を本発明の性能を妨げない範囲で配合することができ、また、その製造方法は、通常化粧料を製造する方法であり、とくに限定されない。これらの原料、成分は、リポソームの内水相でも外水相でも、またその両側にあってもさしつかえない。 In addition to the above ingredients, the liposome dispersion for cosmetics of the present invention usually contains ingredients such as aqueous ingredients, alcohols, oils, surfactants, powders, water-soluble polymers, animals and plants. Natural extracts, various nutrients, moisturizers, cell activators, ultraviolet absorbers, antioxidants, preservatives, fragrances, inorganic salts, various drugs, etc. can be blended within the range that does not interfere with the performance of the present invention, Moreover, the manufacturing method is a method which manufactures cosmetics normally, and is not specifically limited. These raw materials and components can be present either on the inner aqueous phase or the outer aqueous phase of the liposome, or on both sides thereof.
本発明の化粧料に用いるリポソーム分散液は、リン脂質と上記配合成分を公知の技術により混合し、超音波処理法、フレンチプレス法、逆相蒸発法、界面活性剤法、エクストルージョン法、カルシウム−ＥＤＴＡキレート法、凍結融解法、また、真空乳化機、高圧ホモミキサー、マイクロフルイダイザー、マントンゴーリンなどの乳化機で処理することにより得ることができる。また、これらのリポソーム分散液をフィルターやゲルろ過などのサイジング操作により、粒子径のそろったリポソームを選択的に得ることができ、さらにリポソームの安定性を高めることもできる。
本発明におけるリポソームは、平均粒径１００〜５００ｎｍであり、粒径が安定性や感触にも影響を与えるため、粒径をそろえた方が好ましく、粒径のそろったリポソーム分散液を得るためには、エクストルーダーを使用してリポソームをサイジングすることが好ましい。具体的には、エクストルーダーを用いて水和したリン脂質またはリポソームを６０〜８０℃に加温した後、加温した状態で加圧してセルロースやポリカーボネートなどのフィルターを通過させる方法で、フィルターの孔径は０．１〜０．５μｍが好ましく、フィルターの材質は孔径が均一で揃っているポリカーボネート製を用いるのがより好ましい。また、エクストルージョンを２回以上繰り返し行うことで、より粒径の揃ったリポソームを得ることができるようになる。
The liposome dispersion used in the cosmetic composition of the present invention is prepared by mixing phospholipid and the above-mentioned ingredients by a known technique, ultrasonic treatment method, French press method, reverse phase evaporation method, surfactant method, extrusion method, calcium. -It can obtain by processing by emulsifiers, such as a EDTA chelate method, a freeze-thaw method, and a vacuum emulsifier, a high-pressure homomixer, a microfluidizer, a manton gorin. In addition, liposomes having a uniform particle diameter can be selectively obtained from these liposome dispersions by a sizing operation such as a filter or gel filtration, and the stability of the liposomes can be further enhanced.
The liposome in the present invention has an average particle size of 100 to 500 nm, and the particle size also affects the stability and feel. Therefore, it is preferable to make the particle size uniform, and in order to obtain a liposome dispersion liquid having a uniform particle size. Preferably size the liposomes using an extruder. Specifically, a phospholipid or liposome hydrated using an extruder is heated to 60 to 80 ° C. and then pressurized in a heated state and passed through a filter such as cellulose or polycarbonate. The pore diameter is preferably 0.1 to 0.5 μm, and the filter material is more preferably made of polycarbonate having a uniform pore diameter. Moreover, it becomes possible to obtain liposomes having a more uniform particle size by repeating the extrusion twice or more.
本発明のリポソーム分散液は、このまま用いてもよいし、水分３重量％以下に乾燥させ、粉末リポソームとしてもよい。本発明の粉末リポソームは、その保存中ににおいなどの劣化が起こりにくく、乾燥状態で高い安定性を有する。さらには、粉末リポソームを水溶液などで水和させることにより、乾燥前の高安定な使用感の良いリポソーム分散液を再度得ることができ、水和後も高い経時安定性を有するので、適用範囲の広い化粧品原料とすることができる。
本発明における粉末リポソームは、乾燥後、水分が３重量％以下であることが好ましく、さらに好ましくは１重量％未満である。水分が３重量％を超える場合には、吸湿して固まりとなってしまい、水へ再水和しにくくなる。
The liposome dispersion liquid of the present invention may be used as it is, or may be dried to a moisture content of 3% by weight or less to form powder liposomes. The powder liposome of the present invention hardly deteriorates during storage, such as odor, and has high stability in a dry state. Furthermore, by hydrating the powder liposomes with an aqueous solution or the like, a highly stable liposome dispersion with good usability before drying can be obtained again, and it has high temporal stability after hydration. A wide range of cosmetic ingredients.
The powder liposomes of the present invention preferably have a water content of 3% by weight or less after drying, and more preferably less than 1% by weight. When the water content exceeds 3% by weight, it absorbs moisture and hardens, making it difficult to rehydrate to water.
本発明における粉末リポソームは、公知の技術で作製することができる。粉末リポソームは、本発明の化粧料用リポソーム分散液をサイジング後、凍結乾燥や噴霧乾燥することにより、乾燥させて得るものである。本発明の化粧料用リポソーム分散液を粉末リポソームとする際、本発明のリポソーム分散液以外の原料、成分を含んでいてもさしつかえない。これらの原料、成分としては、代表的には糖類が挙げられる。糖類を含むと、粉末リポソームを水や水溶液などと混ぜるときに、容易に分散し、さらには乾燥前のリポソームの粒径を維持することができる。
糖としては、通常化粧料などで使用されている糖であれば特段の限定は受けず使用することができ、トレハロース、スクロース、エリスリトール、マルトース、グルコース、キシリトース、ラクトース、ガラクトース、フルクトースなどが例示できる。好ましくはトレハロース、スクロース、エリスリトールである。この場合、粉末リポソームの原料である、本発明のリポソーム分散液中の膜構成成分と糖類の比率は重量比で、２／１〜１／２０が好ましく、１／１〜１／８がより好ましい。さらに好ましくは、１／２〜１／６である。糖類以外では、各種の栄養成分、酸化防止剤、保湿剤、細胞賦活剤などが挙げられる。これらの原料、成分は、リポソームの内水相でも外水相でも、またその両側にあってもさしつかえない。
The powder liposome in the present invention can be prepared by a known technique. The powder liposome is obtained by sizing the liposome dispersion for cosmetics of the present invention, followed by lyophilization or spray drying. When the liposome dispersion for cosmetics of the present invention is made into powder liposomes, it may contain raw materials and components other than the liposome dispersion of the present invention. These raw materials and components typically include saccharides. When the saccharide is contained, the powder liposome can be easily dispersed when mixed with water or an aqueous solution, and the particle size of the liposome before drying can be maintained.
As the sugar, any sugar that is usually used in cosmetics can be used without particular limitation, and examples include trehalose, sucrose, erythritol, maltose, glucose, xylitol, lactose, galactose, fructose, and the like. . Trehalose, sucrose and erythritol are preferred. In this case, the ratio of the membrane constituents and saccharides in the liposome dispersion liquid of the present invention, which is a raw material for powder liposomes, is preferably 2/1 to 1/20, more preferably 1/1 to 1/8 in terms of weight ratio. . More preferably, it is 1/2 to 1/6. Other than saccharides, various nutritional components, antioxidants, humectants, cell activators and the like can be mentioned. These raw materials and components can be present either on the inner aqueous phase or the outer aqueous phase of the liposome, or on both sides thereof.
粉末リポソームの代表的な製造方法としては、凍結乾燥や噴霧乾燥が挙げられる。例えば、本発明のリポソーム分散液に糖類を添加して、このリポソーム分散液を凍結乾燥や噴霧乾燥することにより、粉末リポソームを得ることができる。
また、本発明の粉末リポソームは、乾燥時に１価のアルカリ金属塩を膜構成成分１００重量％に対して２０重量％以下含有することにより、粉末リポソームの水分散性を向上させることができる。１価のアルカリ金属塩とは、例えば、塩化ナトリウム、塩化カリウム、炭酸ナトリウム、炭酸カリウム、水酸化ナトリウム、水酸化カリウム、酢酸ナトリウム、クエン酸ナトリウム、クエン酸カリウムなどであり、ナトリウム塩が好ましく、さらには塩化ナトリウム、クエン酸ナトリウムがさらに好ましい。本発明の粉末リポソームは、乾燥時に１価のアルカリ金属塩を膜構成成分１００重量％に対して２０重量％以下を含有することができ、好ましくは０．５〜１０重量％を含有することができる。１価のアルカリ金属塩を膜構成成分１００重量％に対して２０重量％を超えて含有すると水和後の安定性が悪くなる傾向があり、リポソームが凝集しやすくなることがある。
Typical methods for producing powder liposomes include freeze drying and spray drying. For example, a saccharide is added to the liposome dispersion liquid of the present invention, and the liposome dispersion liquid can be freeze-dried or spray-dried to obtain powder liposomes.
Moreover, the powder liposome of this invention can improve the water dispersibility of a powder liposome by containing 20 weight% or less of monovalent | monohydric alkali metal salt with respect to 100 weight% of film components at the time of drying. The monovalent alkali metal salt is, for example, sodium chloride, potassium chloride, sodium carbonate, potassium carbonate, sodium hydroxide, potassium hydroxide, sodium acetate, sodium citrate, potassium citrate, and the like, and a sodium salt is preferable. Further, sodium chloride and sodium citrate are more preferable. The powdered liposome of the present invention can contain a monovalent alkali metal salt in an amount of 20% by weight or less, preferably 0.5 to 10% by weight, based on 100% by weight of the membrane constituent when dried. it can. When the monovalent alkali metal salt is contained in an amount exceeding 20% by weight with respect to 100% by weight of the membrane constituent, the stability after hydration tends to be deteriorated, and the liposome may be easily aggregated.
本発明における化粧料用リポソーム分散液または化粧料用粉末リポソームは化粧料に配合して用いることができる。
本発明の化粧料用リポソーム分散液または化粧料用リポソームは、化粧料の原料として広範なものに使用でき、例えば、化粧水などの低粘性のものから、クリームなどの高粘性の化粧料などがあげられる。本発明のリポソーム分散液は安定性が良好であるため、低粘性の化粧水に配合しても問題がない。本発明のリポソーム分散液または粉末リポソームを配合する場合、膜構成成分が０．１〜２０重量％の範囲であるように化粧料に用いることが好ましく、膜構成成分０．５〜５重量％の範囲がさらに好ましい。０．１重量％未満である場合、本発明のリポソームの特徴である、肌のなめらかさや保湿性の効果が表れにくく、また、本発明のリポソーム分散液または粉末リポソームは膜構成成分２０重量％を配合することで十分にその効果を発揮することができるので、これを越えての配合はコスト的に問題がある。
本発明の粉末リポソームは、化粧水やジェル、クリームだけでなく、口紅やファンデーションなどのメイクアップ化粧料に配合することもできるし、さらには、粉末リポソームを水和させてから化粧料へ配合することもできる。これらの粉末リポソームは、膜構成成分が０．１〜２０重量％の範囲であるように、化粧料に使用することが好ましく、０．１〜５重量％の範囲がさらに好ましい。粉末リポソームにおいても、膜構成成分の配合が０．１重量％未満である場合、本発明のリポソームの特徴である、肌のなめらかさや保湿性の効果が表れにくく、また、本発明のリポソームは膜構成成分２０重量％を配合することで十分その効果を発揮することができるので、これを越えての配合はコスト的に問題がある。
本発明の化粧料用リポソームまたは化粧料用粉末リポソームを含有する化粧料は、べたつき感がなく、さらさらとした感触で、荒れた肌を整え、つるつるとしたなめらかな肌へと改善するβ-グルカン含有リポソームである。
The liposome dispersion liquid for cosmetics or the powder liposomes for cosmetics in the present invention can be used by blending in cosmetics.
The liposome dispersion liquid for cosmetics or the liposome for cosmetics of the present invention can be used for a wide range of raw materials for cosmetics, for example, from low-viscosity cosmetics such as skin lotions to highly viscous cosmetics such as creams. can give. Since the liposome dispersion liquid of the present invention has good stability, there is no problem even if it is blended into a low-viscosity lotion. When the liposome dispersion or powder liposome of the present invention is blended, it is preferably used in cosmetics so that the membrane constituent is in the range of 0.1 to 20% by weight, and the membrane constituent is 0.5 to 5% by weight. A range is further preferred. When the amount is less than 0.1% by weight, the smoothness of the skin and the moisturizing effect, which are the characteristics of the liposome of the present invention, are difficult to appear, and the liposome dispersion liquid or powder liposome of the present invention contains 20% by weight of membrane constituents. Since the effect can be fully demonstrated by mix | blending, the mixing | blending exceeding this has a problem in cost.
The powder liposomes of the present invention can be blended in makeup cosmetics such as lipsticks and foundations as well as lotions, gels and creams, and further blended into cosmetics after hydrating the powder liposomes. You can also These powder liposomes are preferably used in cosmetics, and more preferably in the range of 0.1 to 5% by weight, so that the membrane component is in the range of 0.1 to 20% by weight. Even in the case of powder liposomes, when the composition of the membrane constituents is less than 0.1% by weight, the smoothness of the skin and the moisturizing effect, which are the characteristics of the liposomes of the present invention, are hardly exhibited. Since the effect can be sufficiently exhibited by blending 20% by weight of the constituent components, blending beyond this is problematic in terms of cost.
The cosmetic containing the cosmetic liposome or cosmetic powder liposome of the present invention has a non-sticky feeling, a smooth touch, and makes rough skin smooth and smooth and smooth. It is a containing liposome.
次に本発明について実施例を挙げて説明する。なお、配合量はすべて重量％である。
実施例および比較例については、表１に示すリン脂質を使用し、表２および表３に記載の配合のリポソームを作製し、以下の項目について評価を行い、結果も表２〜３に示した。なお、リポソームの膜構成成分は、表２および表３における成分１および２である。β-グルカンについては、市販のSymGlucane（Symrise社製）を使用した。SymGlucaneは、グルコースが１，４− １，３−結合したカラスムギ由来のグルカンを処方した水溶液である。SymGlucane中のβ-グルカン濃度は１％であるため、表記してある配合の１／１００がβ−グルカンとなる。
≪評価項目≫
平均粒径、保存安定性、凝集の有無、においの評価、使用感の評価
Next, the present invention will be described with reference to examples. In addition, all compounding quantities are weight%.
About an Example and a comparative example, the phospholipid shown in Table 1 was used, the liposome of the mixing | blending of Table 2 and Table 3 was produced, the following items were evaluated, and the result was also shown in Tables 2-3. . In addition, the membrane component of a liposome is the components 1 and 2 in Table 2 and Table 3. For β-glucan, commercially available SymGlucane (manufactured by Symrise) was used. SymGlucane is an aqueous solution in which glucan derived from oats with 1,4-1,3-linked glucose is formulated. Since the β-glucan concentration in SymGlucane is 1%, 1/100 of the indicated formulation is β-glucan.
≪Evaluation item≫
Average particle size, storage stability, presence / absence of aggregation, evaluation of odor, evaluation of feeling of use
実施例１
表２に示す所定量の配合成分１〜７を６０℃で加熱融解した後、８を溶解させた所定量の成分９（精製水）を添加し、６０℃で３０分間撹拌を行った。この分散液を孔径０．４μｍのポリカーボネートフィルターによりエクストルージョンを行い、実施例１のリポソーム分散液を得た。
実施例２〜４、７
実施例２〜４は、実施例１と同様の方法で行った。また、エクストルージョンは、実施例２、３においては０．３μｍ、実施例４、７においては０．２μｍの孔径のポリカーボネートフィルターを使用し、種々のサイズのリポソーム分散液を得た。
実施例５、６
実施例５、６は、配合成分１〜７を６０℃で加熱融解した後、８を溶解させた所定量の成分９（精製水）を添加し、６０℃で３０分間ホモジナイズを行い、実施例５、６のリポソーム分散液を得た。
Example 1
After predetermined amounts of the blended components 1 to 7 shown in Table 2 were melted by heating at 60 ° C., a predetermined amount of component 9 (purified water) in which 8 was dissolved was added and stirred at 60 ° C. for 30 minutes. This dispersion was subjected to extrusion with a polycarbonate filter having a pore size of 0.4 μm to obtain a liposome dispersion of Example 1.
Examples 2-4, 7
Examples 2 to 4 were performed in the same manner as in Example 1. Extrusion was performed using a polycarbonate filter having a pore size of 0.3 μm in Examples 2 and 3 and 0.2 μm in Examples 4 and 7, and liposome dispersions having various sizes were obtained.
Examples 5 and 6
In Examples 5 and 6, after blending ingredients 1 to 7 at 60 ° C. by heating and melting, a predetermined amount of component 9 (purified water) in which 8 was dissolved was added and homogenized at 60 ° C. for 30 minutes. Liposome dispersions 5 and 6 were obtained.
比較例１
表３に示す所定量の配合成分１〜７を６０℃で加熱融解した後、８を溶解させた所定量の成分９（精製水）を添加し、６０℃で１０分間ホモジナイズを行い、比較例１のリポソーム分散液を得た。
比較例２
表３に示す所定量の配合成分１〜７を６０℃で加熱融解した後、８を溶解させた所定量の成分９（精製水）を添加し、高圧乳化機により乳化し、比較例２のリポソーム分散液を得た。
比較例３、４
比較例３、４は、実施例１と同様の方法で行った。また、エクストルージョンは、比較例３においては孔径０．２μｍ、比較例４においては孔径０．６μｍのポリカーボネートフィルターでエクストルージョンを行い、比較例３、４のリポソーム分散液を得た。
Comparative Example 1
A predetermined amount of ingredients 1 to 7 shown in Table 3 were melted by heating at 60 ° C., then a predetermined amount of component 9 (purified water) in which 8 was dissolved was added, and homogenized at 60 ° C. for 10 minutes. 1 liposome dispersion was obtained.
Comparative Example 2
After heat-melting the predetermined amount of compounding components 1 to 7 shown in Table 3 at 60 ° C., a predetermined amount of component 9 (purified water) in which 8 is dissolved is added and emulsified with a high-pressure emulsifier. A liposome dispersion was obtained.
Comparative Examples 3 and 4
Comparative Examples 3 and 4 were performed in the same manner as in Example 1. Further, the extrusion was carried out with a polycarbonate filter having a pore diameter of 0.2 μm in Comparative Example 3 and a pore diameter of 0.6 μm in Comparative Example 4, and the liposome dispersion liquids of Comparative Examples 3 and 4 were obtained.
≪評価項目≫
〔平均粒径〕
リポソームの粒径は、動的光散乱法（ＮＩＣＯＭＰ ＭＯＤＥＬ ３７０Ａ、Ｐａｒｔｉｃｌｅ Ｓｉｚｉｎｇ Ｓｙｓｔｅｍｓ社製）で測定を行った。
リポソーム分散液（再水和リポソーム液）を脂質濃度０．１％以下になるよう水で希釈したサンプル６５０μＬをガラスチューブ（ＢＯＲＯＳＩＬＩＣＡＴＥガラス、６×５０ｍｍ）に入れ、ＮＩＣＯＭＰ粒度分布計により１５分間の動的光散乱の測定を行い、ＶｅｓｉｃｌｅモードにおけるＧａｕｓｓｉａｎ分布の平均粒径（体積換算）の測定を行った。
[保存安定性]
実施例１〜７、比較例１〜４のリポソーム分散液を透明なガラスバイアルへ入れ密封系とし、４０℃の恒温槽に遮光して静置した。４０℃での保存におけるリポソーム分散液の凝集の有無、においの変化について調べた。それぞれの評価は以下の基準に従って行った。
〔凝集の有無〕
４０℃の恒温槽に静置しておいたサンプルを、その外観変化を目視にて観察し、以下の基準Ａに従い、判定した。○を効果があると判定した。
＜基準Ａ＞
○：３カ月以上凝集が認められない
×：１ヵ月までは、変化が認められないが、その後凝集が見られた。
××：２週間で凝集が認められた。
≪Evaluation item≫
[Average particle size]
The particle size of the liposome was measured by a dynamic light scattering method (NICOMP MODEL 370A, manufactured by Particle Sizing Systems).
650 μL of a sample obtained by diluting the liposome dispersion (rehydrated liposome solution) with water to a lipid concentration of 0.1% or less is placed in a glass tube (BOROSILICATE glass, 6 × 50 mm), and the movement is performed for 15 minutes using a NICOMP particle size distribution meter. The average light scattering was measured, and the average particle size (in volume conversion) of the Gaussian distribution in the Vesicle mode was measured.
[Storage stability]
The liposome dispersions of Examples 1 to 7 and Comparative Examples 1 to 4 were put into a transparent glass vial to form a sealed system, and were left to stand in a thermostatic bath at 40 ° C. while being shielded from light. The presence or absence of aggregation of the liposome dispersion during storage at 40 ° C. and the change in odor were examined. Each evaluation was performed according to the following criteria.
[Presence / absence of aggregation]
The appearance change of the sample that had been allowed to stand in a constant temperature bath at 40 ° C. was visually observed and judged according to the following criteria A. ○ was determined to be effective.
<Criteria A>
○: Aggregation is not observed for 3 months or more. ×: Until 1 month, no change was observed, but aggregation was observed thereafter.
XX: Aggregation was observed in 2 weeks.
〔においの評価〕
４０℃の恒温槽に３ヶ月間静置しておいたサンプルのにおいについて、以下の基準Ｂに従い、判定した。○を効果があると判定した。
＜基準Ｂ＞
経時安定性におけるにおいの評価
○：ほとんど特異臭を認めない
×：わずかに特異臭を感じる
××：特異臭を感じる
〔使用感の評価〕
実施例１〜７、比較例１〜４のリポソーム分散液を皮膚に塗布した際の使用感（べたつき感のなさ、肌のなめらかさ）について、女性１０名により下記の５段階にて評価し、さらにその平均点を基準Ｃに従い、判定した。また、保湿性においては、皮膚に１日２回１週間塗布した後、下記の５段階にて評価し、さらにその平均点を基準Ｃに従い、判定した。◎または○を効果があると判定した。
＜評価＞
５点：非常に良好
４点：良好
３点：普通
２点：不良
１点：非常に不良
＜基準Ｃ＞
◎：平均点４．５点以上
○：平均点３．５点以上４．５点未満
×：平均点２．５点以上３．５点未満
××：平均点２．５点未満
[Odor evaluation]
The odor of the sample that was allowed to stand in a constant temperature bath at 40 ° C. for 3 months was determined according to the following criteria B. ○ was determined to be effective.
<Standard B>
Evaluation of odor in stability over time ○: Almost no specific odor is observed ×: Slightly specific odor is observed XX: Specific odor is felt [Evaluation of feeling of use]
Regarding the feeling of use (no stickiness, smooth skin) when the liposome dispersions of Examples 1 to 7 and Comparative Examples 1 to 4 were applied to the skin, 10 women evaluated the following 5 levels, Further, the average score was determined according to the standard C. In addition, in terms of moisture retention, after applying to the skin twice a day for one week, evaluation was made in the following five stages, and the average score was determined according to criteria C. ◎ or ○ was judged to be effective.
<Evaluation>
5 points: very good 4 points: good 3 points: normal 2 points: defective 1 point: very bad <reference C>
◎: Average point 4.5 points or more ○: Average point 3.5 points or more and less than 4.5 points ×: Average point 2.5 points or more and less than 3.5 points XX: Average point less than 2.5 points
実施例１〜７のリポソーム分散液はすべての性能を満足するものであった。
比較例１のリポソームは粒径が大きく、リポソームの安定性が悪く、べたつき感も生じた。比較例２〜４のリポソーム分散液は、使用したリン脂質の純度やヨウ素価が本発明におけるリン脂質の範囲外であるため、リポソームの安定性に劣るものであり、比較例２は粒径も小さく、凝集が生じ不安定であった。
The liposome dispersions of Examples 1 to 7 satisfied all the performances.
The liposome of Comparative Example 1 had a large particle size, poor liposome stability, and a sticky feeling. The liposome dispersion liquids of Comparative Examples 2 to 4 are inferior in liposome stability because the purity and iodine value of the phospholipid used are outside the range of the phospholipid in the present invention. Small, aggregated and unstable.
『肌効果試験』
実施例１，４および比較例１，３のリポソーム分散液を用いて肌効果試験を行った。
≪評価項目≫
〔肌の状態の改善効果〕
荒れ肌、乾燥を気にしている女性(２５〜５５才)５名ずつに１日２回(朝、夕)、左右の頬にそれぞれ実施例１と比較例１、または、実施例４と比較例３の組合せで塗布し、左右の肌の改善効果について評価した。塗布後１ヵ月後の肌の状態の「肌の潤い」、「肌あれ」、「肌のなめらかさ」、「肌の張り」について改善効果を下記評価基準により評価し、さらにその平均点を基準Ｄに従い、判定した。◎または○を効果があると判定した。
＜評価＞
３点：非常に効果が感じられた
２点：効果が感じられた
１点：どちらともいえない
０点：効果を感じられなかった
＜基準Ｄ＞
◎：平均点２．５点以上
○：平均点１．５点以上２．５点未満
×：平均点０．５点以上１．５点未満
××：平均点０．５点未満
"Skin effect test"
Skin effect tests were performed using the liposome dispersions of Examples 1 and 4 and Comparative Examples 1 and 3.
≪Evaluation item≫
[Improves skin condition]
Example 1 and Comparative Example 1 or Example 4 and Comparative Example on the left and right cheeks twice a day (morning and evening) for five women (25 to 55 years old) who care about rough skin and dryness It applied by the combination of 3 and evaluated about the improvement effect of right and left skin. One month after application, the skin condition “Moisture”, “Feeling”, “Skin smoothness” and “Skin tension” were evaluated for improvement effect according to the following evaluation criteria, and the average score was also used as a reference The determination was made according to D. ◎ or ○ was judged to be effective.
<Evaluation>
3 points: 2 points where the effect was felt 2 points: 1 point where the effect was felt: 0 points that cannot be said to be 0: No effect was felt <Criteria D>
◎: Average point 2.5 points or more ○: Average point 1.5 points or more and less than 2.5 points ×: Average point 0.5 points or more and less than 1.5 points XX: Average point less than 0.5 points
実施例１、４のリポソーム分散液は肌改善効果が見られ、β-グルカン含有リポソームの性能を満足するものであった。
比較例１のリポソーム分散液は、平均粒径が大きいため、ざらつき感を生じ、肌の潤いやなめらかさの改善などの効果に劣っていた。比較例３のリポソーム分散液はリン脂質の純度が低く、肌のなめらかさなどの効果が十分に発揮されなかった。
The liposome dispersions of Examples 1 and 4 exhibited a skin improvement effect and satisfied the performance of β-glucan-containing liposomes.
Since the liposome dispersion liquid of Comparative Example 1 had a large average particle size, it produced a feeling of roughness and was inferior in effects such as improvement of skin moisture and smoothness. The liposome dispersion liquid of Comparative Example 3 had low phospholipid purity, and effects such as smooth skin were not sufficiently exhibited.
『粉末リポソーム試験』
実施例８〜１０、比較例５、６
表１に示されるリン脂質を用いて、実施例、比較例のリポソーム分散液にトレハロースと塩化ナトリウムを配合して凍結乾燥を行い、粉末リポソームとした。粉末リポソームの保存安定性について、以下の項目について評価を行った。
《評価項目》
粉末リポソームの分散性、粉末リポソームの保存安定性、再水和リポソーム液の安定性
"Powder liposome test"
Examples 8 to 10, Comparative Examples 5 and 6
Using the phospholipids shown in Table 1, trehalose and sodium chloride were added to the liposome dispersions of Examples and Comparative Examples and freeze-dried to obtain powdered liposomes. The following items were evaluated for the storage stability of the powdered liposomes.
"Evaluation item"
Dispersibility of powder liposome, storage stability of powder liposome, stability of rehydrated liposome liquid
実施例８
表２に示す所定量の実施例１の配合成分１〜７を６０℃で加熱融解した後、成分８、トレハロース６重量％、塩化ナトリウム０．０５重量％を成分９（精製水）（成分１〜９、トレハロース６重量％、塩化ナトリウム０．０５重量％を含めて全量を１００重量％とする）に溶解させた水溶液を成分１〜８に添加し、６０℃で３０分間撹拌を行った。この分散液を孔径０．４μｍのポリカーボネートフィルターによりエクストルージョンを行い、リポソーム分散液を得た。凍結乾燥を行い、実施例８の粉末リポソームを得た。
実施例９
表２に示す所定量の実施例２の配合成分１〜７を６０℃で加熱融解した後、成分８、トレハロース１２重量％、塩化ナトリウム０．４重量％を成分９（精製水）（成分１〜９、トレハロース１２重量％、塩化ナトリウム０．４重量％を含めて全量を１００重量％とする）に溶解させた水溶液を成分１〜８に添加し、６０℃で３０分間撹拌を行った。この分散液を孔径０．３μｍのポリカーボネートフィルターによりエクストルージョンを行い、リポソーム分散液を得た後、凍結乾燥を行い、実施例９の粉末リポソームを得た。
実施例１０
表２に示す所定量の実施例４の配合成分１〜７を６０℃で加熱融解した後、成分８、トレハロース１０重量％を成分９（精製水）（成分１〜９、トレハロース１０重量％を含めて全量を１００重量％とする）に溶解させた水溶液を成分１〜８に添加し、６０℃で３０分間撹拌を行った。この分散液を孔径０．２μｍのポリカーボネートフィルターによりエクストルージョンを行い、リポソーム分散液を得た後、凍結乾燥を行い、実施例１０の粉末リポソームを得た。
Example 8
A predetermined amount of the components 1 to 7 of Example 1 shown in Table 2 were heated and melted at 60 ° C., and then component 8, trehalose 6% by weight, sodium chloride 0.05% by weight was component 9 (purified water) (component 1 To 9 and 6% by weight of trehalose and 0.05% by weight of sodium chloride to make the total amount 100% by weight) were added to components 1 to 8 and stirred at 60 ° C. for 30 minutes. This dispersion was subjected to extrusion with a polycarbonate filter having a pore size of 0.4 μm to obtain a liposome dispersion. Lyophilization was performed to obtain the powder liposome of Example 8.
Example 9
A predetermined amount of the components 1 to 7 of Example 2 shown in Table 2 were heated and melted at 60 ° C., and then component 8, trehalose 12% by weight, sodium chloride 0.4% by weight was component 9 (purified water) (component 1 To 9 and 12% by weight of trehalose and 0.4% by weight of sodium chloride to make the total amount 100% by weight) were added to components 1 to 8 and stirred at 60 ° C. for 30 minutes. This dispersion was subjected to extrusion with a polycarbonate filter having a pore size of 0.3 μm to obtain a liposome dispersion, and then freeze-dried to obtain the powder liposome of Example 9.
Example 10
After heat-melting the compounding components 1 to 7 of Example 4 shown in Table 2 at 60 ° C., component 8 and trehalose 10% by weight are added to component 9 (purified water) (components 1 to 9 and trehalose 10% by weight are added. An aqueous solution dissolved in 100% by weight in total was added to components 1 to 8, and stirred at 60 ° C. for 30 minutes. This dispersion was subjected to extrusion with a polycarbonate filter having a pore size of 0.2 μm to obtain a liposome dispersion, followed by lyophilization to obtain the powder liposome of Example 10.
比較例５
表３に示す所定量の比較例１の配合成分１〜７を６０℃で加熱融解した後、成分８、トレハロース１０重量％、塩化ナトリウム１．６重量％を成分９（精製水）（成分１〜９、トレハロース１０重量％、塩化ナトリウム１．６重量％を含めて全量を１００重量％とする）に溶解させた水溶液を成分１〜８に添加し、６０℃で３０分間ホモジナイズを行い、リポソーム分散液を得た後、凍結乾燥を行い、比較例５の粉末リポソームを得た。
比較例６
表３に示す所定量の比較例３の配合成分１〜７を６０℃で加熱融解した後、成分８、トレハロース１０重量％、塩化ナトリウム０．２重量％を成分９（精製水）（成分１〜９、トレハロース１０重量％、塩化ナトリウム０．２重量％を含めて全量を１００重量％とする）に溶解させた水溶液を成分１〜８に添加し、６０℃で３０分間撹拌を行った。この分散液を孔径０．２μｍのポリカーボネートフィルターによりエクストルージョンを行い、リポソーム分散液を得た後、凍結乾燥を行い、比較例６の粉末リポソームを得た。
Comparative Example 5
A predetermined amount of the blended components 1-7 of Comparative Example 1 shown in Table 3 were heated and melted at 60 ° C., then component 8, trehalose 10% by weight, sodium chloride 1.6% by weight, component 9 (purified water) (component 1 To 9 and 10% by weight of trehalose and 1.6% by weight of sodium chloride to make the total amount 100% by weight), added to components 1 to 8, homogenized at 60 ° C. for 30 minutes, and liposomes After obtaining the dispersion, freeze-drying was performed to obtain the powder liposome of Comparative Example 5.
Comparative Example 6
A predetermined amount of blended components 1 to 7 of Comparative Example 3 shown in Table 3 were heated and melted at 60 ° C., and then component 8, trehalose 10% by weight, sodium chloride 0.2% by weight was component 9 (purified water) (component 1 To 9 and 10% by weight of trehalose and 0.2% by weight of sodium chloride to make the total amount 100% by weight) were added to components 1 to 8 and stirred at 60 ° C. for 30 minutes. This dispersion was subjected to extrusion with a polycarbonate filter having a pore size of 0.2 μm to obtain a liposome dispersion, followed by lyophilization to obtain the powder liposome of Comparative Example 6.
≪評価項目≫
表５に示す粉末リポソームおよび再水和リポソーム液について下記の評価を行い、その結果も表５に示した。
１）粉末リポソームの分散性
〔分散性の評価〕
粉末リポソームをスクリュー管の中に入れ、膜構成成分が１％となるよう水を加え、手で振とうし分散性について、基準Ｅに従い、判定した。◎または○を効果があると判定した。
＜基準Ｅ＞
◎：良好、１〜２回の振とうですべてが分散する
○：３〜５回の振とうですべて分散し、塊がない
×：６〜１０回振とうしてすべて分散し、塊がない
××：１０回振とうしても塊が残る
２）粉末リポソームの保存安定性
〔においの評価〕
粉末リポソームをアルミ袋に密封して保存し、４０℃恒温槽に静置し、１週間、３ヶ月後の粉末リポソームのにおいについて、基準Ｂに従い、判定した。○を効果があると判定した。
３）再水和リポソームの保存安定性
〔凝集の有無〕
粉末リポソームを４０℃１ヶ月静置したサンプルについて、再水和させた後、透明なガラスバイアルに入れて４０℃で保存し、その外観変化を目視にて観察し、以下の基準Ａに従い、判定した。○を効果があると判定した。
〔においの評価〕
粉末リポソームを４０℃１ヶ月静置したサンプルについて、再水和させた後、透明なガラスバイアルに入れて４０℃で保存し、再水和リポソーム液のにおいについて、基準Ｂに従い、判定した。○を効果があると判定した。
〔使用感の評価〕
実施例８〜１０、比較例５、６の再水和リポソーム液を皮膚に塗布した際の使用感（べたつき感のなさ・肌のなめらかさ）について、女性１０名により下記の５段階にて評価し、さらにその平均点を基準Ｄに従い、判定した。また、保湿性においては、皮膚に１日２回１週間塗布した後、下記の５段階にて評価し、さらにその平均点を基準Ｃに従い、判定した。◎または○を効果があると判定した。
＜評価＞
５点：非常に良好
４点：良好
３点：普通
２点：不良
１点：非常に不良
≪Evaluation item≫
The following evaluation was performed on the powdered liposomes and rehydrated liposome solution shown in Table 5, and the results are also shown in Table 5.
1) Dispersibility of powder liposomes [Evaluation of dispersibility]
Powdered liposomes were placed in a screw tube, water was added so that the membrane component was 1%, and shaking was performed by hand to determine dispersibility according to standard E. ◎ or ○ was judged to be effective.
<Standard E>
◎: Good, all dispersed by shaking 1-2 times ○: All dispersed by shaking 3-5 times, no lump ×: All dispersed by shaking 6-10 times, no lump XX: A lump remains even after shaking 10 times 2) Storage stability of powdered liposomes [Odor evaluation]
The powder liposomes were stored sealed in an aluminum bag, left in a constant temperature bath at 40 ° C., and the smell of the powder liposomes after 1 week and 3 months was determined according to the standard B. ○ was determined to be effective.
3) Storage stability of rehydrated liposomes [presence / absence of aggregation]
After rehydrating the powder liposomes at 40 ° C for 1 month, put them in a transparent glass vial, store them at 40 ° C, visually observe the appearance change, and judge according to the following criteria A did. ○ was determined to be effective.
[Odor evaluation]
The sample in which the powder liposomes were allowed to stand at 40 ° C. for 1 month was rehydrated and then placed in a transparent glass vial and stored at 40 ° C., and the odor of the rehydrated liposome solution was determined according to Standard B. ○ was determined to be effective.
[Evaluation of feeling of use]
The feeling of use (no stickiness / smoothness of skin) when the rehydrated liposome solutions of Examples 8 to 10 and Comparative Examples 5 and 6 were applied to the skin was evaluated by the following 10 levels by 10 women. Further, the average score was determined according to the standard D. In addition, in terms of moisture retention, after applying to the skin twice a day for one week, evaluation was made in the following five stages, and the average score was determined according to criteria C. ◎ or ○ was judged to be effective.
<Evaluation>
5 points: very good 4 points: good 3 points: normal 2 points: bad 1 point: very bad
実施例の粉末リポソームはすべての性能を満足するものであった。
比較例５の粉末リポソームは、平均粒径が大きいため、塗布時にざらつきを生じ、使用感に劣っていた。また、１価のアルカリ金属塩の含有量が膜構成成分にたいして請求範囲外であるため安定性が悪く、再水和後のリポソーム液は１ヶ月後には凝集・沈殿した。比較例６の粉末リポソームは再水和後の粒径が大きかったため、水和後１ヶ月で沈殿を生じ、安定性が悪かった。
『リポソームの評価』
実施例１１〜１３、比較例７〜９
実施例４および比較例４のリポソーム分散液、実施例８および比較例６の粉末リポソームを用いて、表６に示す化粧水、表７に示すクリームを作製し、下記の評価を行った。
〔化粧水の製造法〕
１） 表６に示す成分８（精製水）に成分１、２、６を室温にて溶解した。
２） さらに成分３〜５、７を溶解させ、１）に混合可溶化した。
The powder liposomes of the examples satisfied all the performances.
Since the powder liposome of Comparative Example 5 had a large average particle size, it produced roughness during application and was inferior in usability. Further, since the content of the monovalent alkali metal salt was outside the scope of the claims for the membrane constituents, the stability was poor, and the liposome solution after rehydration aggregated and precipitated after one month. Since the powder liposome of Comparative Example 6 had a large particle size after rehydration, precipitation occurred in one month after hydration and the stability was poor.
"Evaluation of liposomes"
Examples 11-13, Comparative Examples 7-9
Using the liposome dispersion liquid of Example 4 and Comparative Example 4 and the powder liposomes of Example 8 and Comparative Example 6, skin lotions shown in Table 6 and creams shown in Table 7 were prepared and evaluated as follows.
[Manufacturing method of lotion]
1) Components 1, 2, and 6 were dissolved in component 8 (purified water) shown in Table 6 at room temperature.
2) Further, components 3 to 5 and 7 were dissolved and mixed and solubilized in 1).
〔クリームの製造法〕
１）表７に示す成分１〜８を８０℃に加温し、よく混練りした。
２）成分９〜１９も８０℃に加温し、よく混練りした。
３） １）と２)を混合分散させ、室温まで冷却してクリームを得た。
[Production method of cream]
1) Components 1 to 8 shown in Table 7 were heated to 80 ° C. and kneaded well.
2) Components 9 to 19 were also heated to 80 ° C. and kneaded well.
3) 1) and 2) were mixed and dispersed, and cooled to room temperature to obtain a cream.
≪評価項目≫
下記の評価を行い、化粧水、クリームについてそれぞれ評価を行った。結果をそれぞれ表８、９に示す。
〔使用感の評価〕
実施例１１〜１３、比較例７〜９の化粧料を皮膚に塗布した際の使用感（べたつき感のなさ・肌のなめらかさ）について、パネル１０名により下記の５段階にて評価し、さらにその平均点を基準Ｄに従い、判定した。また、保湿性においては、皮膚に１日２回１週間塗布した後、下記の５段階にて評価し、さらにその平均点を基準Ｃに従い、判定した。◎または○を効果があると判定した。
<評価>
５点：非常に良好
４点：良好
３点：普通
２点：不良
１点：非常に不良
〔肌の状態の改善効果〕
荒れ肌、乾燥を気にしている女性(２５〜５５才)５名ずつに１日２回(朝、夕)、左右の頬にそれぞれ実施例１１と比較例７、実施例１２と比較例８、実施例１３と比較例９といった組合せで塗布し、左右の肌の改善効果について評価した。塗布後１ヵ月後の肌の状態の「肌の潤い」、「肌あれ」、「肌のなめらかさ」、「肌の張り」について改善効果を下記評価基準により評価し、さらにその平均点を基準Ｄに従い、判定した。◎または○を効果があると判定した。
＜評価＞
３点：非常に効果が感じられた
２点：効果が感じられた
１点：どちらともいえない
０点：効果を感じられなかった
≪Evaluation item≫
The following evaluation was performed, and each of the lotion and the cream was evaluated. The results are shown in Tables 8 and 9, respectively.
[Evaluation of feeling of use]
The feeling of use (no stickiness / smoothness of skin) when the cosmetics of Examples 11 to 13 and Comparative Examples 7 to 9 were applied to the skin was evaluated by the 10 panelists in the following 5 levels. The average score was determined according to criteria D. Further, in terms of moisturizing properties, the coating was applied to the skin twice a day for one week, and then evaluated according to the following five levels. ◎ or ○ was judged to be effective.
<Evaluation>
5 points: very good 4 points: good 3 points: normal 2 points: bad 1 point: very bad [improvement of skin condition]
Two women (25 to 55 years old) who are worried about rough skin and dryness twice a day (morning and evening), Example 11 and Comparative Example 7, Example 12 and Comparative Example 8, respectively on the left and right cheeks, It applied by the combination of Example 13 and Comparative Example 9, and evaluated the improvement effect of the left and right skin. One month after application, the skin condition “Moisture”, “Feeling”, “Smoothness” and “Skin tension” were evaluated for the improvement effect according to the following evaluation criteria, and the average score was also determined The determination was made according to D. ◎ or ○ was judged to be effective.
<Evaluation>
3 points: 2 points where the effect was felt very much 1 point where the effect was felt 1 point which cannot be said to be 0: No effect was felt
実施例のリポソーム分散液または粉末リポソームはすべての性能を満足するものであった。
比較例７、８のリポソーム分散液または粉末リポソームはリン脂質の純度が低く、また粒径も大きいため肌のなめらかさなどの効果が十分に発揮されなかった。
The liposome dispersions or powder liposomes of the examples satisfied all the performances.
The liposome dispersions or powder liposomes of Comparative Examples 7 and 8 have low phospholipid purity and a large particle size, so that the effects such as the smoothness of the skin were not sufficiently exhibited.
実施例の粉末リポソームはすべての性能を満足するものであった。
比較例９の粉末リポソームはリン脂質の純度が低く、また粒径も大きいため肌のなめらかさなどの効果が十分に発揮されなかった。
The powder liposomes of the examples satisfied all the performances.
The powder liposome of Comparative Example 9 had a low phospholipid purity and a large particle size, so that the effects such as the smoothness of the skin were not sufficiently exhibited.
Claims (7)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006021906A JP2007204381A (en) | 2006-01-31 | 2006-01-31 | β-glucan-containing liposome for cosmetics |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006021906A JP2007204381A (en) | 2006-01-31 | 2006-01-31 | β-glucan-containing liposome for cosmetics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2007204381A true JP2007204381A (en) | 2007-08-16 |
Family
ID=38484158
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006021906A Pending JP2007204381A (en) | 2006-01-31 | 2006-01-31 | β-glucan-containing liposome for cosmetics |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2007204381A (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009120584A (en) * | 2007-09-26 | 2009-06-04 | Lvmh Recherche | Cosmetic composition in form of emulsion comprising continuous aqueous phase and dispersed fatty phase and preparation method thereof |
| JP2009235010A (en) * | 2008-03-27 | 2009-10-15 | Kose Corp | Skincare preparation for external use |
| JP2010215556A (en) * | 2009-03-17 | 2010-09-30 | Asahi Kasei Chemicals Corp | External composition for skin, improved in skin permeability |
| JP2015214520A (en) * | 2014-05-13 | 2015-12-03 | 株式会社ノムラ | Calanthe discolor extract |
| JP2018131398A (en) * | 2017-02-14 | 2018-08-23 | 株式会社Adeka | Agent for improving the emulsion stability of emulsion composition, and cosmetic composition containing the same |
| JP2021046442A (en) * | 2020-12-24 | 2021-03-25 | 株式会社Adeka | Emulsion stability improver for emulsion composition, and cosmetic composition comprising the same |
| JP2022114409A (en) * | 2021-01-26 | 2022-08-05 | 株式会社アルビオン | Cosmetic composition and method for producing the same |
| CN115944751A (en) * | 2022-12-09 | 2023-04-11 | 牡丹江医学院附属红旗医院 | Nuclear magnetic resonance contrast agent for diagnosing cerebral thrombosis and application thereof |
-
2006
- 2006-01-31 JP JP2006021906A patent/JP2007204381A/en active Pending
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009120584A (en) * | 2007-09-26 | 2009-06-04 | Lvmh Recherche | Cosmetic composition in form of emulsion comprising continuous aqueous phase and dispersed fatty phase and preparation method thereof |
| JP2009235010A (en) * | 2008-03-27 | 2009-10-15 | Kose Corp | Skincare preparation for external use |
| JP2010215556A (en) * | 2009-03-17 | 2010-09-30 | Asahi Kasei Chemicals Corp | External composition for skin, improved in skin permeability |
| JP2015214520A (en) * | 2014-05-13 | 2015-12-03 | 株式会社ノムラ | Calanthe discolor extract |
| JP2018131398A (en) * | 2017-02-14 | 2018-08-23 | 株式会社Adeka | Agent for improving the emulsion stability of emulsion composition, and cosmetic composition containing the same |
| JP2021046442A (en) * | 2020-12-24 | 2021-03-25 | 株式会社Adeka | Emulsion stability improver for emulsion composition, and cosmetic composition comprising the same |
| JP7053779B2 (en) | 2020-12-24 | 2022-04-12 | 株式会社Adeka | An emulsifying stability improver for an emulsifying composition, and a cosmetic composition containing the same. |
| JP2022114409A (en) * | 2021-01-26 | 2022-08-05 | 株式会社アルビオン | Cosmetic composition and method for producing the same |
| CN115944751A (en) * | 2022-12-09 | 2023-04-11 | 牡丹江医学院附属红旗医院 | Nuclear magnetic resonance contrast agent for diagnosing cerebral thrombosis and application thereof |
| CN115944751B (en) * | 2022-12-09 | 2023-10-31 | 牡丹江医学院附属红旗医院 | Nuclear magnetic resonance contrast agent for diagnosing cerebral thrombosis and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007204381A (en) | β-glucan-containing liposome for cosmetics | |
| CN114392198A (en) | A kind of cosmetic composition and preparation method thereof | |
| CN101583339A (en) | Compositions comprising macromolecular assemblies of lipid and surfactant | |
| US20090317437A1 (en) | Cellulose gel formulations | |
| US20100003292A1 (en) | Fine-granulometry fungal extract chitine-glucane | |
| JP4304352B2 (en) | Transdermal absorption control agent containing sophorolipid and method for producing the same | |
| JP2020055852A (en) | Cosmetic composition for wrinkle reduction containing gypenoside isolated from gynostemma pentaphyllum | |
| JP7589932B2 (en) | Oil-in-water emulsion composition | |
| JP7211818B2 (en) | Skin topical agent | |
| JP5261680B2 (en) | Hyaluronic acid propylene glycol ester and topical skin preparation using the same | |
| JP7383867B2 (en) | Emulsified composition for skin | |
| JP4731301B2 (en) | Moisturizer and cosmetics containing the same | |
| JP2010235491A (en) | Liposomes for cosmetics | |
| CN109568178A (en) | A kind of nanometer of micro emulsion composition and its nano micro-emulsification cosmetic of preparation | |
| JP5140913B2 (en) | Coenzyme Q10-containing liposome for cosmetics | |
| KR102138733B1 (en) | Cosmetic composition for wrinkle improvement containing phospholipid nano-structure | |
| JP2006124378A (en) | Liposomes for cosmetics | |
| KR102458630B1 (en) | Cubosome composition containing retinal and covalent organic framework, and cosmetic composition comprising thereof | |
| CN114515248B (en) | Oil-in-water nanoemulsion and preparation method and application thereof | |
| CA2880756C (en) | Natural personal care cream to powder compositions | |
| JP2013129638A (en) | Cosmetic material | |
| JP7512010B2 (en) | Composition for transdermal absorption and method for improving transdermal absorbability | |
| JP4748650B2 (en) | Sheet cosmetic | |
| KR101178595B1 (en) | Two-layered cosmetics | |
| JP4592347B2 (en) | External preparation composition |